A.R.T.I.C

Arctic Therapeutics is a clinical-stage biotechnology company based in Iceland that focuses on the development of therapies for rare genetic diseases and neurodegenerative disorders. The company's primary focus is on hereditary cystatin C amyloid angiopathy (HCCAA), a rare genetic disease prevalent in Iceland that causes early-onset stroke and dementia. Arctic Therapeutics leverages Iceland's unique genetic data and clinical resources to identify and validate therapeutic targets. Their pipeline includes small molecules and antisense oligonucleotides designed to inhibit the formation of toxic amyloid aggregates. Beyond its lead program in HCCAA, the company is exploring treatments for more common conditions such as Alzheimer disease and psoriasis.